WHAT'S NEW
FDA Approves Recapturable, Self-expandable TAVR System
Cardiology Today's Intervention: On June 23 Medtronic announced that it has received Food and Drug Administration approval for a new recapturable, self-expanding system for transcatheter aortic valve replacement for treatment of patients with severe aortic stenosis who are at high or extreme risk for surgery. The CoreValve Evolut R System device is the first recapturable, self-expanding, transcatheter heart valve approved in the United States. CONTINUE TO STORY
FDA Approves SAPIEN 3 THV Artificial Heart Valve
FDA: On June 17, the U.S. Food and Drug Administration today approved the SAPIEN 3 Transcatheter Heart Valve (THV) for patients with a narrowing in the heart's aortic valve, called aortic valve stenosis. The SAPIEN 3 THV is approved for patients with aortic valve stenosis who are inoperable or at high risk for death or complications associated with open-heart surgery. ADDITIONAL INFORMATION
Building a Better Valve
New York Times: The New York Times profiles the TAVR story, a wonderful example of a transformative technology that began with an idea many dismissed. This story also illustrates how TAVR is part of the changing face of cardiac care in the United States. READ ON
Image Review
 What Happened to the Valve?
Daniel H. Steinberg, MD reviews a rare case of Ventricular Embolization the case of an 89 year old patient with a history of chronic systolic heart failure. This case features lots of learning points. REVIEW
Image Review
 Coronary Obstruction During Transcatheter Aortic Valve Replacement
Christian Spies, MD, FSCAI reviews this rare case, discussing the factors of coronary obstruction in TAVR and several take home points. TAKE A LOOK
|